More recent experiments, involving the administration of a part CBD part THC solution, have yielded results that contradict the first supposition. At present, on the evidence that cannabidiol reduces some of the psychoactive effects of tetrahydrocannabinol (acting as a de facto antidepressant), scientists argue that cannabidiol has a holistic but indirect influence on all cannabinoid receptors in the endocannabinoid system. The main consequence of this impact seems to be an increase in the production of endocannabinoids. This is now the prevailing idea that accounts for the mountains of empirical evidence of how the benefits of cannabidiol are expressed at the cellular level.
Current studies, including one carried out by the UC San Diego School of Medicine, are looking into how the endocannabinoid system may be linked to reducing symptoms associated with autism. This is due to its role in social reward responsivity, neural development and circadian rhythm and anxiety regulation – all of which are often affected by autism. (52)
Then there is the matter of which part of the plant is used. THC tends to be more concentrated in the leaves of the plant, while CBD in its stem and seeds. It should be noted that these aspects are relative. Some degree of agreement exists that for the purest CBD, the stalk of a hemp plant (varieties of cannabis generally grown for fiber manufacturing, low in THC), or much less often the seeds. Taking into account the fact that CBD supplements are usually in an oil form, one may fathom the origins of the nearly ubiquitous hemp oil dietary supplements.